Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-MINE + X
- Development stage
- Unknown
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
R-MINE + X is a combination chemotherapy and targeted therapy regimen used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The base regimen, R-MINE, consists of rituximab (a monoclonal anti-CD20 antibody), mitoxantrone hydrochloride liposome (an anthracycline anti-tumor drug), ifosfamide (an alkylating agent), and etoposide (an topoisomerase II inhibitor). In the R-MINE + X protocol, patients receive one cycle of R-MINE followed by stratification based on gene subtype to receive an additional targeted agent ("X"), which varies depending on molecular characteristics. This approach aims to improve efficacy and safety in patients with relapsed/refractory DLBCL by personalizing therapy according to tumor genetics[2].
- Other names
- R-MINE+XRMINE+X
02
Targets
Beyond the preview
Go deeper on R-MINE + X.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-MINE + X.